In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
暂无分享,去创建一个
B H Arison | B. Ma | Jianguo Zhao | T. Prueksaritanont | B. Arison | D E Slaughter | T Prueksaritanont | B Ma | L Liu | J J Zhao | L M Gorham | X Yu | K P Vyas | D. Slaughter | K. Vyas | L. Liu | X. Yu | L. Gorham | Lida Liu | J. J. Zhao | Xiao Yu | Lynn M. Gorham
[1] S. Pond,et al. Metabolic disposition of simvastatin in patients with T-tube drainage. , 1994, Drug metabolism and disposition: the biological fate of chemicals.
[2] P. Neuvonen,et al. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. , 1995, Clinical pharmacology and therapeutics.
[3] S. Kitareewan,et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. , 1994, Biochemistry.
[4] W. Trager,et al. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients. , 1994, The Journal of pharmacology and experimental therapeutics.
[5] D. Waxman,et al. Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. , 1994, Archives of biochemistry and biophysics.
[6] J. Hochman,et al. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. , 1996, Drug metabolism and disposition: the biological fate of chemicals.
[7] R Monaghan,et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[8] P. Neuvonen,et al. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole , 1994 .
[9] V. F. Mauro. Clinical Pharmacokinetics and Practical Applications of Simvastatin , 1993, Clinical pharmacokinetics.
[10] Jouni Ahonen,et al. The Effect of the Systemic Antimycotics, Itraconazole and Fluconazole, on the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Midazolam , 1996, Anesthesia and analgesia.
[11] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[12] H. Thijssen,et al. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics , 1993, British journal of pharmacology.
[13] I. Chen,et al. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[14] T. Prueksaritanont,et al. Species differences in the metabolism of a potent HIV-1 reverse transcriptase inhibitor L-738,372. In vivo and in vitro studies in rats, dogs, monkeys, and human. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[15] H. Yamazaki,et al. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. , 1992, Carcinogenesis.
[16] T. Leemann,et al. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.
[17] T. Shimada,et al. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. , 1991, Chemical research in toxicology.
[18] A. Y. Lu,et al. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes. , 1995, Drug metabolism and disposition: the biological fate of chemicals.
[19] C. Wandel,et al. Midazolam is metabolized by at least three different cytochrome P450 enzymes. , 1994, British journal of anaesthesia.
[20] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[21] D. Greenblatt,et al. Midazolam Hydroxylation by Human Liver Microsomes In Vitro: Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents , 1996, Journal of clinical pharmacology.
[22] T. Kamataki,et al. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. , 1993, The Journal of pharmacology and experimental therapeutics.
[23] G R Wilkinson,et al. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. , 1977, The Journal of pharmacology and experimental therapeutics.
[24] J. Miners,et al. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. , 1988, Biochemical pharmacology.
[25] A. Y. Lu,et al. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.
[26] T. Prueksaritanont,et al. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver. , 1995, Biochemical pharmacology.
[27] E. Grau,et al. Simvastatin-oral anticoagulant interaction , 1996, The Lancet.
[28] B. Arison,et al. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. , 1990, Drug metabolism and disposition: the biological fate of chemicals.
[29] R. J. Gerson,et al. Comparison of Plasma Profiles of Lovastatin (Mevinolin), Simvastatin (Epistatin) and Pravastatin (Eptastatin) in the Dog , 1990 .